CLINICAL_TRIALS
trial_result
· 2025-05-29
Clinical Trial Update: Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome [Phase 3]
Summary
Phase 3 trial evaluating ANX005 for Guillain-Barré syndrome has completed, investigating efficacy and safety.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Annexon, Inc. | Conditions: Guillain-Barre Syndrome | Phase 3 | Status: COMPLETED